Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All HCQ studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19hcq.org COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Effect of combination therapy of hydroxychloroquine and azithromycin on mortality in COVID-19 patients

Lauriola et al., Clinical and Translational Science, doi:10.1111/cts.12860
Sep 2020  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Mortality 74% Improvement Relative Risk HCQ for COVID-19  Lauriola et al.  LATE TREATMENT Is late treatment with HCQ beneficial for COVID-19? Retrospective 360 patients in Italy Lower mortality with HCQ (p=0.001) c19hcq.org Lauriola et al., Clinical and Translat.., Sep 2020 FavorsHCQ Favorscontrol 0 0.5 1 1.5 2+
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
 
*, now with p < 0.00000000001 from 411 studies, recognized in 46 countries.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,300+ studies for 75 treatments. c19hcq.org
Retrospective 377 patients, 73% reduction in mortality with HCQ+AZ, adjusted hazard ratio HR 0.27 [0.17-0.41]. Mean age 71.8. No serious adverse events. Subject to incomplete adjustment for confounders.
risk of death, 73.5% lower, HR 0.27, p < 0.001, treatment 102 of 297 (34.3%), control 35 of 63 (55.6%), NNT 4.7, adjusted per study.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Lauriola et al., 14 Sep 2020, retrospective, Italy, peer-reviewed, mean age 71.8, 10 authors.
This PaperHCQAll
Effect of Combination Therapy of Hydroxychloroquine and Azithromycin on Mortality in Patients With COVID‐19
Marinella Lauriola, Arianna Pani, Giovanbattista Ippoliti, Andrea Mortara, Stefano Milighetti, Marjieh Mazen, Gianluca Perseghin, Daniele Pastori, Paolo Grosso, Francesco Scaglione
Clinical and Translational Science, doi:10.1111/cts.12860
Conflicting evidence regarding the use of hydroxychloroquine (HCQ) and azithromycin for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection do exist. We performed a retrospective single-center cohort study including 377 consecutive patients admitted for pneumonia related to coronavirus disease 2019 (COVID-19). Of these, 297 were in combination treatment, 17 were on HCQ alone, and 63 did not receive either of these 2 drugs because of contraindications. The primary end point was in-hospital death. Mean age was 71.8 ± 13.4 years and 34.2% were women. We recorded 146 deaths: 35 in no treatment, 7 in HCQ treatment group, and 102 in HCQ + azithromycin treatment group (log rank test for Kaplan-Meier curve P < 0.001). At multivariable Cox proportional hazard regression analysis, age (hazard ratio (HR) 1.057, 95% confidence interval (CI) 1.035-1.079, P < 0.001), mechanical ventilation/continuous positive airway pressure (HR 2.726, 95% CI 1.823-4.074, P < 0.001), and C reactive protein above the median (HR 2.191, 95% CI 1.479-3.246, P < 0.001) were directly associated with death, whereas use of HCQ + azithromycin (vs. no treatment; HR 0.265, 95% CI 0.171-0.412, P < 0.001) was inversely associated. In this study, we found a reduced in-hospital mortality in patients treated with a combination of HCQ and azithromycin after adjustment for comorbidities. A large randomized trial is necessary to confirm these findings.
Conflict of Interest. All authors declared no competing interests for this work. Author Contributions. M.L., A.P., G.I., A.M., S.M., M.M., G.P., D.P., P.G., and F.S. wrote the manuscript. A.P., F.S., and M.L. designed the research. D.P. analyzed the data.
References
Al-Kofahi, Finding the dose for hydroxychloroquine prophylaxis for COVID-19: the desperate search for effectiveness, Clin. Pharmacol. Ther, doi:10.1002/cpt.1874
Arnold, Buckner, Hydroxychloroquine for treatment of SARS-CoV-2 infection? Improving our confidence in a model-based approach to dose selection, Clin. Transl. Sci
Beigel, Remdesivir for the treatment of Covid-19 -preliminary report, N. Engl. J. Med, doi:10.1056/NEJMoa2007764
Bessiere, Assessment of QT intervals in a case series of patients with coronavirus disease 2019 (COVID-19) infection treated with hydroxychloroquine alone or in combination with azithromycin in an intensive care unit, JAMA Cardiol, doi:10.1001/jamacardio.2020.1787
Bonow, Hernandez, Turakhia, Hydroxychloroquine, coronavirus disease 2019, and QT prolongation, JAMA Cardiol, doi:10.1001/jamacardio.2020.1782
Cao, A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19
Chang, Inpatient use of ambulatory telemetry monitors for COVID-19 patients treated with hydroxychloroquine and/or azithromycin, J. Am. Coll. Cardiol
Cory, Impact of azithromycin treatment on macrophage gene expression in subjects with cystic fibrosis, J. Cyst. Fibros
Fantini, Chahinian, Yahi, Synergistic antiviral effect of hydroxychloroquine and azithromycin in combination against SARS-CoV-2: what molecular dynamics studies of virus-host interactions reveal, Int. J. Antimicrob. Agents, doi:10.1016/j.ijantimicag.2020.106020
Gao, Ray, Xiao, Ray, Suppression of inducible nitric oxide synthase expression and nitric oxide production by macrolide antibiotics in sulfur mustard-exposed airway epithelial cells, Basic Clin. Pharmacol. Toxicol
Gautret, Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, Int. J. Antimicrob. Agents, doi:10.1016/j.ijantimicag.2020.105949
Geleris, Observational study of hydroxychloroquine in hospitalized patients with Covid-19, N. Engl. J. Med
Humeniuk, Safety, tolerability, and pharmacokinetics of remdesivir, an antiviral for treatment of COVID-19, in healthy subjects, Clin. Transl. Sci, doi:10.1111/cts.12840
Kawamura, Efficacy of azithromycin in sepsis-associated acute respiratory distress syndrome: a retrospective study and propensity score analysis, Springerplus
Kawamura, Ichikado, Takaki, Eguchi, Anan et al., Adjunctive therapy with azithromycin for moderate and severe acute respiratory distress syndrome: a retrospective, propensity score-matching analysis of prospectively collected data at a single center, Int. J. Antimicrob. Agents
Lauriola, Hydroxychloroquine and Azithromycin in COVID-19
Lippi, South, Henry, Electrolyte imbalances in patients with severe coronavirus disease 2019 (COVID-19), Ann. Clin. Biochem
Liu, Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro, Cell Discov
Magagnoli, Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19, doi:10.1101/2020.04.16.20065920
Mercuro, Risk of QT interval prolongation associated with use of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients testing positive for coronavirus disease, JAMA Cardiol, doi:10.1001/jamacardio.2020.1834
Naksuk, Lazar, Peeraphatdit, Cardiac safety of off-label COVID-19 drug therapy: a review and proposed monitoring protocol, Eur. Heart J. Acute Cardiovasc. Care
Pani, Marinella, Romandini, Scaglione, Macrolides and viral infections: focus on azithromycin in COVID-19 pathology, Int. J. Antimicrob. Agents, doi:10.1016/j.ijantimicag.2020.106053
Perinel, Towards optimization of hydroxychloroquine dosing in intensive care unit COVID-19 patients, Clin. Infect. Dis, doi:10.1093/cid/ciaa394
Rosenberg, Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York state, JAMA
Tang, Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial, BMJ
Yao, In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2), Clin. Infect. Dis, doi:10.1093/cid/ciaa237
Yeo, Impact of disease on plasma and lung exposure of chloroquine, hydroxy-chloroquine and azithromycin: application of PBPK modelling, Clin. Pharmacol. Ther, doi:10.1002/cpt.1955
Zhaowei Chen, Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial, doi:10.1101/2020.03.22.20040758
Zimmermann, Ziesenitz, Curtis, Ritz, The immunomodulatory effects of macrolides-a systematic review of the underlying mechanisms, Front. Immunol
{ 'indexed': {'date-parts': [[2024, 3, 24]], 'date-time': '2024-03-24T02:01:13Z', 'timestamp': 1711245673219}, 'reference-count': 28, 'publisher': 'Wiley', 'issue': '6', 'license': [ { 'start': { 'date-parts': [[2020, 10, 13]], 'date-time': '2020-10-13T00:00:00Z', 'timestamp': 1602547200000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': 'http://creativecommons.org/licenses/by-nc/4.0/'}], 'content-domain': {'domain': ['ascpt.onlinelibrary.wiley.com'], 'crossmark-restriction': True}, 'published-print': {'date-parts': [[2020, 11]]}, 'abstract': '<jats:p>Conflicting evidence regarding the use of hydroxychloroquine (HCQ) and azithromycin ' 'for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection ' 'do exist. We performed a retrospective single‐center cohort study including 377 consecutive ' 'patients admitted for pneumonia related to coronavirus disease 2019 (COVID‐19). Of these, 297 ' 'were in combination treatment, 17 were on HCQ alone, and 63 did not receive either of these 2 ' 'drugs because of contraindications. The primary end point was in‐hospital death. Mean age was ' '71.8\xa0±\xa013.4\xa0years and 34.2% were women. We recorded 146 deaths: 35 in no treatment, ' '7 in HCQ treatment group, and 102 in HCQ\xa0+\xa0azithromycin treatment group (log rank test ' 'for Kaplan–Meier curve <jats:italic>P</jats:italic>\xa0&lt;\xa00.001). At multivariable Cox ' 'proportional hazard regression analysis, age (hazard ratio (HR) 1.057, 95% confidence ' 'interval (CI) 1.035–1.079, <jats:italic>P</jats:italic>\xa0&lt;\xa00.001), mechanical ' 'ventilation/continuous positive airway pressure (HR 2.726, 95% CI 1.823–4.074, ' '<jats:italic>P</jats:italic>\xa0&lt;\xa00.001), and C reactive protein above the median (HR ' '2.191, 95% CI 1.479–3.246, <jats:italic>P</jats:italic>\xa0&lt;\xa00.001) were directly ' 'associated with death, whereas use of HCQ\xa0+\xa0azithromycin (vs. no treatment; HR 0.265, ' '95% CI 0.171–0.412, <jats:italic>P</jats:italic>\xa0&lt;\xa00.001) was inversely associated. ' 'In this study, we found a reduced in‐hospital mortality in patients treated with a ' 'combination of HCQ and azithromycin after adjustment for comorbidities. A large randomized ' 'trial is necessary to confirm these findings.</jats:p>', 'DOI': '10.1111/cts.12860', 'type': 'journal-article', 'created': {'date-parts': [[2020, 9, 16]], 'date-time': '2020-09-16T07:33:36Z', 'timestamp': 1600241616000}, 'page': '1071-1076', 'update-policy': 'http://dx.doi.org/10.1002/crossmark_policy', 'source': 'Crossref', 'is-referenced-by-count': 34, 'title': 'Effect of Combination Therapy of Hydroxychloroquine and Azithromycin on Mortality in Patients ' 'With COVID‐19', 'prefix': '10.1111', 'volume': '13', 'author': [ { 'given': 'Marinella', 'family': 'Lauriola', 'sequence': 'first', 'affiliation': [{'name': 'Infectious Disease Department Policlinico di Monza Monza Italy'}]}, { 'given': 'Arianna', 'family': 'Pani', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Oncology and Hemato‐Oncology Università degli ' 'Studi di Milano Milan Italy'}]}, { 'given': 'Giovanbattista', 'family': 'Ippoliti', 'sequence': 'additional', 'affiliation': [{'name': 'Internal Medicine Department Policlinico di Monza Monza Italy'}]}, { 'given': 'Andrea', 'family': 'Mortara', 'sequence': 'additional', 'affiliation': [{'name': 'Cardiology Department Policlinico di Monza Monza Italy'}]}, { 'given': 'Stefano', 'family': 'Milighetti', 'sequence': 'additional', 'affiliation': [{'name': 'Internal Medicine Department Policlinico di Monza Monza Italy'}]}, { 'given': 'Marjieh', 'family': 'Mazen', 'sequence': 'additional', 'affiliation': [{'name': 'Internal Medicine Department Policlinico di Monza Monza Italy'}]}, { 'given': 'Gianluca', 'family': 'Perseghin', 'sequence': 'additional', 'affiliation': [ {'name': 'Internal Medicine Department Policlinico di Monza Monza Italy'}, { 'name': 'Department of Medicine and Surgery Università degli Studi di ' 'Milano Bicocca Milan Italy'}]}, { 'given': 'Daniele', 'family': 'Pastori', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Clinical, Internal, Anesthesiologic, and ' 'Cardiovascular Sciences Sapienza University of Rome Rome ' 'Italy'}]}, { 'given': 'Paolo', 'family': 'Grosso', 'sequence': 'additional', 'affiliation': [{'name': 'Intensive Care Unit Policlinico di Monza Monza Italy'}]}, { 'given': 'Francesco', 'family': 'Scaglione', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Oncology and Hemato‐Oncology Università degli ' 'Studi di Milano Milan Italy'}]}], 'member': '311', 'published-online': {'date-parts': [[2020, 10, 13]]}, 'reference': [ {'key': 'e_1_2_8_1_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NEJMoa2001282'}, { 'key': 'e_1_2_8_2_1', 'article-title': 'Remdesivir for the treatment of Covid‐19 ‐ preliminary report', 'author': 'Beigel J.H.', 'journal-title': 'N. Engl. J. Med.'}, { 'key': 'e_1_2_8_3_1', 'article-title': 'Safety, tolerability, and pharmacokinetics of remdesivir, an antiviral ' 'for treatment of COVID‐19, in healthy subjects', 'author': 'Humeniuk R.', 'journal-title': 'Clin. Transl. Sci.'}, { 'key': 'e_1_2_8_4_1', 'article-title': 'Efficacy of hydroxychloroquine in patients with COVID‐19: results of a ' 'randomized clinical trial', 'author': 'Zhaowei Chen J.H.', 'journal-title': 'medRxiv'}, { 'key': 'e_1_2_8_5_1', 'article-title': 'Outcomes of hydroxychloroquine usage in United States veterans ' 'hospitalized with Covid‐19', 'author': 'Magagnoli J.', 'journal-title': 'medRxiv'}, {'key': 'e_1_2_8_6_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NEJMoa2012410'}, {'key': 'e_1_2_8_7_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1136/bmj.m1849'}, { 'key': 'e_1_2_8_8_1', 'article-title': 'Hydroxychloroquine and azithromycin as a treatment of COVID‐19: results ' 'of an open‐label non‐randomized clinical trial', 'author': 'Gautret P.', 'journal-title': 'Int. J. Antimicrob. Agents.'}, {'key': 'e_1_2_8_9_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1186/s40064-016-2866-1'}, { 'key': 'e_1_2_8_10_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.ijantimicag.2018.02.009'}, {'key': 'e_1_2_8_11_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.jcf.2013.08.007'}, {'key': 'e_1_2_8_12_1', 'doi-asserted-by': 'publisher', 'DOI': '10.3389/fimmu.2018.00302'}, { 'key': 'e_1_2_8_13_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1111/j.1742-7843.2008.00255.x'}, {'key': 'e_1_2_8_14_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1001/jama.2020.8630'}, { 'key': 'e_1_2_8_15_1', 'article-title': 'Macrolides and viral infections: focus on azithromycin in COVID‐19 ' 'pathology', 'author': 'Pani A.', 'journal-title': 'Int. J. Antimicrob. Agents'}, {'key': 'e_1_2_8_16_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1177/2048872620922784'}, { 'key': 'e_1_2_8_17_1', 'article-title': 'Finding the dose for hydroxychloroquine prophylaxis for COVID‐19: the ' 'desperate search for effectiveness', 'author': 'Al‐Kofahi M.', 'journal-title': 'Clin. Pharmacol. Ther.'}, {'key': 'e_1_2_8_18_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/s41421-020-0156-0'}, { 'key': 'e_1_2_8_19_1', 'article-title': 'In vitro antiviral activity and projection of optimized dosing design ' 'of hydroxychloroquine for the treatment of severe acute respiratory ' 'syndrome Coronavirus 2 (SARS‐CoV‐2)', 'author': 'Yao X.', 'journal-title': 'Clin. Infect. Dis.'}, { 'key': 'e_1_2_8_20_1', 'article-title': 'Towards optimization of hydroxychloroquine dosing in intensive care ' 'unit COVID‐19 patients', 'author': 'Perinel S.', 'journal-title': 'Clin. Infect. Dis'}, {'key': 'e_1_2_8_21_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1111/cts.12797'}, { 'key': 'e_1_2_8_22_1', 'article-title': 'Impact of disease on plasma and lung exposure of chloroquine, ' 'hydroxy‐chloroquine and azithromycin: application of PBPK modelling', 'author': 'Rowland Yeo K.', 'journal-title': 'Clin. Pharmacol. Ther.'}, { 'key': 'e_1_2_8_23_1', 'article-title': 'Synergistic antiviral effect of hydroxychloroquine and azithromycin in ' 'combination against SARS‐CoV‐2: what molecular dynamics studies of ' 'virus‐host interactions reveal', 'author': 'Fantini J.', 'journal-title': 'Int. J. Antimicrob. Agents'}, { 'key': 'e_1_2_8_24_1', 'article-title': 'Hydroxychloroquine, coronavirus disease 2019, and QT prolongation', 'author': 'Bonow R.O.', 'journal-title': 'JAMA Cardiol.'}, { 'key': 'e_1_2_8_25_1', 'article-title': 'Risk of QT interval prolongation associated with use of ' 'hydroxychloroquine with or without concomitant azithromycin among ' 'hospitalized patients testing positive for coronavirus disease 2019 ' '(COVID‐19)', 'author': 'Mercuro N.J.', 'journal-title': 'JAMA Cardiol.'}, { 'key': 'e_1_2_8_26_1', 'article-title': 'Assessment of QT intervals in a case series of patients with ' 'coronavirus disease 2019 (COVID‐19) infection treated with ' 'hydroxychloroquine alone or in combination with azithromycin in an ' 'intensive care unit', 'author': 'Bessiere F.', 'journal-title': 'JAMA Cardiol.'}, {'key': 'e_1_2_8_27_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.jacc.2020.04.032'}, {'key': 'e_1_2_8_28_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1177/0004563220922255'}], 'container-title': 'Clinical and Translational Science', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fcts.12860', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://onlinelibrary.wiley.com/doi/pdf/10.1111/cts.12860', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://onlinelibrary.wiley.com/doi/full-xml/10.1111/cts.12860', 'content-type': 'application/xml', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://ascpt.onlinelibrary.wiley.com/doi/pdf/10.1111/cts.12860', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2023, 9, 4]], 'date-time': '2023-09-04T09:28:23Z', 'timestamp': 1693819703000}, 'score': 1, 'resource': {'primary': {'URL': 'https://ascpt.onlinelibrary.wiley.com/doi/10.1111/cts.12860'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2020, 10, 13]]}, 'references-count': 28, 'journal-issue': {'issue': '6', 'published-print': {'date-parts': [[2020, 11]]}}, 'alternative-id': ['10.1111/cts.12860'], 'URL': 'http://dx.doi.org/10.1111/cts.12860', 'relation': {}, 'ISSN': ['1752-8054', '1752-8062'], 'subject': [ 'General Pharmacology, Toxicology and Pharmaceutics', 'General Biochemistry, Genetics and Molecular Biology', 'General Medicine', 'General Neuroscience'], 'container-title-short': 'Clinical Translational Sci', 'published': {'date-parts': [[2020, 10, 13]]}, 'assertion': [ { 'value': '2020-06-23', 'order': 0, 'name': 'received', 'label': 'Received', 'group': {'name': 'publication_history', 'label': 'Publication History'}}, { 'value': '2020-07-13', 'order': 1, 'name': 'accepted', 'label': 'Accepted', 'group': {'name': 'publication_history', 'label': 'Publication History'}}, { 'value': '2020-10-13', 'order': 2, 'name': 'published', 'label': 'Published', 'group': {'name': 'publication_history', 'label': 'Publication History'}}]}
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit